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Abstract 3 
Binge Eating Disorder (BED) is the most prevalent specific eating disorder in the world 4 
and its main feature is the binge consumption of high-calorie foods in a short period of 5 
time, without any compensatory strategies. BED patients show a large risk for obesity 6 
and its associated medical comorbidities, as for numerous psychiatric disorders. 7 
Negative affectivity, body image disturbance and stress are all possible triggers; 8 
however, these patients present with altered reward sensitivity, reflecting structural 9 
differences found in fMRI studies. The three main goals of treatment are achieving a 10 
reduction in binge-eating episodes, and, ultimately, abstinence; weight loss and 11 
remission of the comorbid psychiatric conditions. Serotonin-Selective Reuptake 12 
Inhibitors (SSRIs) are the best studied medication for BED; however, their use, both 13 
isolated and in combination with psychological-behavioral therapies, has been reported 14 
to have inferior results than the isolated application of Cognitive Behavioral Therapy 15 
(CBT), the current gold standard treatment for this disease. Nevertheless, with 16 
moderate remission rates and considerable drop-out rates, there is the imperative need 17 
to explore other therapeutic approaches for BED, either as an alternative or a 18 
complement to CBT. In the 1990s there began to emerge the presently called “third-19 
wave” behavioural therapies, in which are included the Mindfulness-Based 20 
Interventions (MBIs), a set of programs that incorporate the recent concept of 21 
mindfulness to psychotherapy. In this review, there is presented the current evidence 22 
on the potential benefit of these new therapies to treat BED and what challenges there 23 
are to face in order for them to be recognized and implemented.   24 
Key-words: Binge Eating Disorder; Obesity; Cognitive Behavioral Therapy; 25 
Mindfulness; Mindfulness-Based Interventions26 
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Introduction 53 
Binge eating is a behaviour characterized by the uncontrolled consumption of 54 
an objectively large amount of food in a discrete period of time, as described by the 55 
American Psychiatric Association. The concept was first mentioned in the literature by 56 
Stunkard in 1959 [1] and was included in the fourth edition of the Diagnostic and 57 
Statistical Manual of Mental Disorders (DSM-IV) in 1994, inside the category of Eating 58 
Disorder Not Otherwise Specified (EDNOS) [2]. Only recently it has been distinguished 59 
as the core behavioural feature of Binge Eating Disorder (BED), a now distinct 60 
psychiatric diagnosis defined in the latest, fifth edition of the Diagnostic and Statistical 61 
Manual of Mental Disorders (DSM-5) [3]. According to the latter, for one to be 62 
diagnosed with BED, there must exist recurrent and persistent episodes of binge 63 
eating, at least once a week, during a minimum of three months, which are associated 64 
with a sense of loss of control [3]. This last aspect is often described by patients as an 65 
inability to stay away from food or to stop eating. Binge eaters usually consume high-66 
calorie foods, rich in fat, and/or sugar [3].  67 
BED is the most prevalent specific eating disorder, affecting 3.5% of adult 68 
women and 2.0% of adult men in the USA [4]. BED appears to occur with similar 69 
frequencies in most developed countries and the World Mental Health Survey 70 
estimated an average lifetime prevalence of BED at 1.9% across surveys [5]. BED 71 
usually firstly manifests itself in teenagers or young adults, but it can arise later, in 72 
adulthood [3]. Treatment-seeking individuals with BED tend to be older than ones with 73 
Anorexia Nervosa (AN) or Bulimia Nervosa (BN) [3]. Concerning gender prevalence, 74 
BED affects almost twice more women than it does men, although this difference is 75 
greater on other eating disorders [6].      76 
 77 
 78 
 79 
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Binge eating used to be thought mainly as a maladaptive behaviour 80 
characterizing Bulimia Nervosa (BN), which makes it the main differential diagnosis of 81 
BED [3]. However, both pathologies differ largely, as inappropriate compensatory 82 
manoeuvres, such as purging, excessive physical exercise and use of laxative 83 
medication, only occur in BN. Furthermore, BED patients present superior successful 84 
treatment and remission rates than BN and other eating disorders, and this greater 85 
prognosis exists even if no treatment is established. Also, these individuals, despite 86 
experimenting with feelings of body and weight shame between binge episodes, don’t 87 
exhibit clear dieting restriction to lose weight, differing from those with BN [3].  88 
One of the most important aspects of BED is its marked association with 89 
obesity, although BED can affect both obese and non-obese patients. This association 90 
is particularly strong within treatment-seeking patients, with BED affecting 4 to 8% of 91 
obese individuals and 30% of those who are also dieting [7].   92 
Obesity in BED patients manifests itself differently when comparing with their 93 
non-BED counterparts, showing different ages of onset, eating patterns, severity and 94 
evolution; they present with greater weight and body shape concerns, role impairment, 95 
and higher frequencies of concomitant psychiatric disorders [8], with 67% to 79% of 96 
BED patients presenting with at least one lifetime comorbid psychiatric diagnosis, 97 
including depression, anxiety, manic-depressive disorders, posttraumatic stress, body 98 
dysmorphic disorders and substance abuse [9]. Incidentally, the craving and loss of 99 
control found in BED patients can be matched to the craving for psychotropic 100 
substances and the loss of control over their use seen in persons with addiction [10]. 101 
Indeed, it has been lately studied the potential concept of the term food addiction and 102 
the consequent potential treatment benefits of substance abuse targeted medications 103 
in BED, due to this found association [10]. Related to these likely co-occurring 104 
diagnoses is an elevated suicide risk, which is significant even after controlling for 105 
mood disorders, i.e. depression [11]. It’s relevant to note that this psychiatric 106 
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comorbidity is related to the severity of the compulsive symptoms, and not to the 107 
degree of obesity [3].  108 
Another crucial part of the disorder’s comorbidity is the greater risk for obesity-109 
associated medical pathologies, namely metabolic syndrome, diabetes mellitus and 110 
hypertension, which diminishes their quality of life and increases mortality [8]. The 111 
severity of the disease depends on the weekly frequency of binge eating episodes, 112 
furtherly acknowledging associated symptoms and the level of functional impairment 113 
[3].  114 
There have been postulated various theories on the basis of the 115 
pathophysiology of BED, particularly the motive for binge eating behavior. The Affect 116 
Regulation Model regards bingeing as a way to decrease negative affectivity, a concept 117 
long known and described as emotional eating [12]. This remains the most common 118 
trigger for compulsive eating, whether followed by compensatory behaviours or not. 119 
BED patients report binge eating in order to improve mood and diminish stress and not 120 
for physical satisfaction [13]. However, after the short-term alleviating effect of this 121 
behaviour, comes negative self-evaluation and dysphoria [14]. 122 
Negative affectivity and stress can originate from multiple factors, and one of 123 
them may be the overconcern, or even shame, of one’s own body shape or weight [15]. 124 
Body image disturbance, although not included in the diagnostic criteria for BED, might 125 
be an important component of the disease’s psychopathology, influencing negatively 126 
the disease’s prognosis [16], and a potential target for treatment [17]. 127 
Similarly, the Escape Awareness Theory suggests that binge eating is intended 128 
to avoid negative emotion [13]. On the other hand, the Cognitive Theory explains binge 129 
eating as a momentary escape from restricted eating [18]. However, one model 130 
considers the three theories mentioned above, the Dual Pathway Model, and it is 131 
crucial to understanding the key potential role of mindfulness-based therapies 132 
scrutinized later in this essay [19].  133 
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It’s known that BED appears commonly in certain families, thus genetic 134 
predisposition may be important [3].   135 
The current evidence shows that individuals suffering from this disease 136 
demonstrate unique traits that can be recognized clinically and by medical imaging, by 137 
means of functional Magnetic Resonance Imaging (fMRI). There has been established 138 
that these patients present with alterations in reward sensitivity, as evidenced by 139 
differential activation of reward-related brain areas upon stimulation with calorie-rich 140 
food cues. These results are accompanied by structural alterations in these same 141 
areas.  142 
Not only have BED patients increased sensitivity to food reward, they present 143 
with alterations in generalized reward sensitivity, showing a global hypo 144 
responsiveness to non-food cues [20]. The only fMRI study that has examined non-145 
food reward processing in this population, using monetary incentives, demonstrated a 146 
decreased ventral striatum recruitment in the BED obese group, when comparing to 147 
non-BED controls [21]. The ventral striatum region of the brain is crucial to both the 148 
engagement of goal-oriented behaviours and affective stance [22]. 149 
In conclusion, there is to confirm the hypothesis that these individuals have 150 
diminished responses to wide-ranging stimuli which might represent a susceptible state 151 
that can be temporarily overcome by the ingestion of palatable foods. 152 
One of the elements that help to define compulsivity, with its various forms of 153 
manifestation, in which is included pathological overeating, is the inability to stop the 154 
continued behaviour despite its aversive consequences [23]. This trait reflects a lack of 155 
inhibitory control processes which, in turn, are regulated by the prefrontal cortex (PFC) 156 
and cortico-striatal circuitries [24]. This is one common feature between BED and 157 
substance addiction, among other shared psychological, emotional, behavioural and 158 
genetic traits [25].  159 
 160 
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There have been defined two opposing systems when it comes to reward 161 
processing and inhibitory control functions: the “GO” system, comprising the 162 
dorsolateral PFC, anterior cingulate cortex and orbitofrontal cortex and the “STOP” 163 
system, contemplating the ventromedial PFC. During binge eating episodes, the first 164 
component is sensitized while the latter is compromised [26]. The role played by these 165 
brain regions in value representation and consequent choice behaviour makes it easy 166 
to understand the main behavioural features of the disease [20]. 167 
Another trait that distinguishes BED patients from their healthy peers is their 168 
different perception and expression of emotions and their differential use of emotion 169 
regulation strategies, both adaptive and maladaptive (reappraisal, acceptance, 170 
avoidance, rumination, suppression, among others) [11]. Summarizing, the main 171 
impairment they present is the shortage of adaptive strategies to deal with negative 172 
affectivity [27]. They have greater suppression mechanisms while their reappraise is 173 
diminished [28]. Rumination concerning the comparison of one’s present 174 
circumstances to ideal expectations, especially when it involves body image, seems to 175 
increase negative mental and emotional stances, and it might be correlated with the 176 
disease’s severity [29]. 177 
There are also particularities in various neurotransmitter systems co-occurring 178 
with binge eating in BED patients, with differential activities in the dopaminergic, 179 
serotoninergic, acetilcolinergic and endogenous opioid systems. Food intake is partially 180 
regulated by brain circuits involved in pleasure, motivation and positive behaviour 181 
reinforcement, thus these alterations are noted in reward-associated brain areas [30]. 182 
Animal models of binge eating suggest that bingeing on sugary or fatty diets causes a 183 
repeated release of dopamine (DA) in the Nucleus Accumbens and consonantly, BED 184 
patients demonstrated expressively greater extracellular DA levels in the caudate 185 
nucleus in response to food cues, comparing with non-BED obese controls [31, 32]. 186 
Raclopride, a DA antagonist, has shown to reduce food intake, although with 187 
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differential results according to the macronutrient consumed [33]. Laboratory 188 
experiments on the aforementioned models have shown that opioid receptors’ 189 
antagonists reduce food intake [33]. Serotonin has been associated with satiety and, 190 
therefore, to weight loss. Acetylcholine levels peak at one’s full feeding state [34]; 191 
however, its release is delayed with bingeing [35].  192 
With its recent distinction as a main diagnostic condition, BED is starting to be 193 
established as a significant public health problem, not only due to its greater relative 194 
prevalence when compared to other longer recognized and better studied eating 195 
disorders, i.e. AN and BN, but also due to its associated substantial medical, 196 
psychological and social burden. Therefore, the importance of a soon effective 197 
treatment solution that covers both dimensions of this disease. 198 
 199 
 200 
 201 
 202 
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 209 
8 
  
 
Development 210 
The three main goals in the treatment of BED are achieving a reduction in the 211 
frequency of binge episodes, and, ultimately, abstinence, promoting sustained weight 212 
loss, and treating the coexistent psychiatric disorders (e.g., increasing positive mood, 213 
attenuating undue self-image concerns). Of the scales used to provide knowledge on 214 
the severity of binge eating, reference to the Binge Eating Scale [36] and the Eating 215 
Disorder Examination Questionnaire [37]. In some studies, emotional eating might be 216 
addressed, through the Dutch Eating Behaviour Questionnaire [38] and the Three-217 
Factor Eating Questionnaire [39], for example. 218 
The most commonly tested outcomes are the frequency of binge eating 219 
episodes, the primary outcome measure in nearly all Randomized Controlled Trials 220 
(RCTs), weight loss and treatment completion rates, which reflects treatment 221 
tolerability [40]. 222 
 223 
Pharmacotherapy 224 
Antidepressants, antiepileptics, anti-obesity agents, “anti-craving” agents and 225 
stimulants classically linked to Attention Deficit Hyperactivity Disorder, have all been 226 
tested as isolated treatments for BED [40]. 227 
Selective Serotonin Reuptake Inhibitors (SSRIs) are the best studied 228 
medication for BED, perhaps due to the demonstrated efficacy and consequent  229 
approval by the Food and Drug Administration (FDA) of fluoxetine for BN [41]. 230 
Fluoxetine, fluvoxamine, sertraline and citalopram have been shown to expressively 231 
reduce the number of binge eating episodes and to promote weight loss in BED 232 
patients [42, 43], while studies with escitalopram have shown mixed results [44]. 233 
Despite their short-term ability to reduce symptomatology, binge-eating abstinence 234 
rates did not differ significantly from placebo with these medications [42]. Furthermore, 235 
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one systematic review was explicit on the lack of sufficient evidence to propose 236 
antidepressants as first line of treatment [45].  237 
Atomoxetine, a norepinephrine reuptake inhibitor, has shown significant 238 
reductions in binge-eating episode frequency, binge day frequency, weight as well in a 239 
number of secondary outcomes, such as severity of illness, obsessive-compulsive 240 
symptomatology and hunger. Most importantly, some patients reached binge-eating 241 
remission with atomoxetine [46].  242 
Along with its efficacy in significantly decreasing binge eating frequency and, 243 
more notably, achieving binge eating remission, topiramate is, currently, the medication 244 
to induce the most substantial weight loss in patients with BED. However, its high 245 
adverse event and dropout rates are to be taken in account [47]. Zonisamide is another 246 
antiepileptic drug known to have positive results on weight loss. Despite being 247 
efficacious in reducing binge eating episode frequency and body weight, it didn’t induce 248 
binge remission and it was not well tolerated, with patients referring physical, 249 
psychological and cognitive impairment [48]. Lamotrigine, with the exception of weight 250 
loss and metabolic parameters, did not differ from placebo in any of the outcomes 251 
tested [49]. 252 
Lisdexamfetamine (LDX) is the prodrug of d-amphetamine and the first 253 
medication to be approved by the FDA for the treatment of moderate to severe BED, as 254 
it proved superior to placebo in both primary and secondary binge-related outcomes, 255 
from baseline [50]. The long-term results were consistent with its continued use [51]. 256 
It’s important to mention that LDX is not, however, indicated for weight loss [52]. 257 
There have been very few studies testing anti-obesity medications for BED, i.e. 258 
orlistat, but, as expected, orlistat significantly improved weight loss but did not prove to 259 
be efficacious in reducing binge eating frequency, even when added to Cognitive 260 
Behavioural Therapy (CBT) [53]. Other medications have been tested, such as 261 
chromium picolinate, for its glucose regulation proprieties [54] or armodafinil, that 262 
showed optimistic results, albeit in small sample sizes [55]. 263 
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The literature on pharmacological treatment solutions for BED remains limited, 264 
as the majority of the studies on this subject have been projected in very small, non-265 
diverse samples, with short follow-up times [4]. There is a large collection of non-RCT 266 
studies on this matter as well, therefore disabling comparisons with placebo, which 267 
plays a major role in mental-illness populations. Long before the launch of the DSM-5 268 
criteria for BED, Cooper Z. et al were already recognizing that the concept of BED as it 269 
was postulated in DSM-IV was a contributor to heterogenous research samples, which 270 
were including non-BED patients [56].  The overwhelming amount of pharmacotherapy 271 
studies existing currently were made prior to DSM-5, and, therefore, that can be 272 
another limitation to their results. 273 
 274 
Cognitive Behavioral Therapy  275 
Treatment approaches comprising pharmacotherapies only, particularly SSRIs, 276 
were shown inferior to CBT in the treatment of BED, which makes the latter the current 277 
gold standard treatment for this disease [57]. CBT has shown important reductions in 278 
binge-eating frequency and improvements in self-evaluation, mood and coping 279 
mechanisms [58]. However, it showed no influence on weight or weight-related quality 280 
of life [58, 59]. Remission rates range from 40 to 60%, meaning about 50% of patients 281 
remain symptomatic after therapy [57]. Average drop-out rates are of 25% [60]. 282 
 283 
 284 
 285 
 286 
 287 
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Pharmacotherapy + CBT 288 
The outcomes achieved with combination approaches, adding 289 
pharmacotherapy to behavioral therapies, i.e. CBT, were superior to those of 290 
medication alone, but inferior to the isolated application of CBT [61]. 291 
Nevertheless, some studies have shown a few exceptions. Topiramate has 292 
potentialized the results achieved with CBT, with less dropout rates [62]. The addition 293 
of zonisamide produced higher reductions of binge episodes and greater weight loss 294 
[63].  295 
 296 
“Third-wave” behavior therapies and the concept of mindfulness 297 
Hayes et al. have described the field of behaviour therapy as three overlapping 298 
historical generations or “waves” [64]. The first generation was born in the 1950s, 299 
disrupting with the psychoanalytic model, dominant at the time [65, 66]. The second 300 
generation corresponds to CBT, recognizing the role of language and cognition in 301 
psychopathology and continues to be the leading therapy approach through the 302 
present day [67].  303 
The “third-wave” behavioural therapies began in the 1990s and are, for the past 304 
decade, gaining increasing exposure and scientific interest [64, 68]. Despite keeping in 305 
mind many concepts from CBT, they target one’s experience of certain emotions and 306 
cognitive processes, and not their content [69]. Therefore, it is promoted a non-307 
judgmental, open and accepting attitude towards aversive internal experiences, may 308 
they be thoughts, feelings, experiences or beliefs, without trying to diminish or avoid 309 
them [66]. These set of skills can be comprised into a concept named mindfulness. 310 
 311 
 312 
 313 
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Although the concept of mindfulness has its ancient origins in the Hinduism and 314 
Buddhism philosophies, only for the past two decades mindfulness techniques have 315 
seen cultural and scientific interest growth, particularly in the field of behaviour therapy 316 
[68]. Due to the recent appearance of the term in the psychology and psychiatry 317 
dictionaries, the precise meaning and underlying concepts of mindfulness are still 318 
difficult to define [66]. Ellen Langer was the first psychologist to describe mindfulness, 319 
referring to it as a “limber state of mind” [70]. However, the words used by mindfulness 320 
pioneer Jon Kabat-Zinn have become the most popular among authors: “paying 321 
attention in a particular way: on purpose, in the present moment, and nonjudgmentally” 322 
[71]. This definition, widely used today, gave us the key ideas of awareness and 323 
acceptance of all immediate, internal experiences, the positive ones and the 324 
undesirable ones [66].  Skills developed under these conceptions aim to decrease 325 
emotional and cognitive reactivity and increase self-acceptance, by encouraging 326 
feelings of compassion and forgiveness towards oneself and others [66]. Individuals 327 
are trained to notice distressing sensations, to learn how to deal and tolerate them, 328 
without mistaken it for hunger, therefore decreasing reactive, automatic, unwanted 329 
responses [72].  330 
The efficacy of mindfulness-related and/or acceptance-based techniques, has 331 
been studied and tested for innumerous psychiatric conditions, specifically depression, 332 
anxiety, substance abuse and PTSD, proving to be potentially beneficial in various 333 
RCTs [73, 74]. Additionally, many of these interventions are being exponentially tested 334 
as a treatment complement in medical, long term, high-comorbid conditions (i.e., 335 
cancer, chronic pain, neurologic disorders) [74, 75].  336 
 337 
 338 
 339 
 340 
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Under the third-generation group of therapies fall the Acceptance and 341 
Commitment Therapy (ACT), the Dialectical Behaviour Therapy (DBT), the 342 
Compassion Mind Training/Compassion-Focused Therapy (CFT), the Functional 343 
Analytic Psychotherapy (FAP), the Behavioural Activation (BA), the Metacognitive 344 
Therapy (MCT) and the Mindfulness-Based Interventions (MBIs) [76]. The difference 345 
between these programs is the dose of mindfulness training each one implements [77]. 346 
MBIs are primary mindfulness interventions, meaning they contain mindfulness training 347 
in every session of treatment; others incorporate mindfulness into a multi-component 348 
treatment approach [77]. Some of these therapies can be widely applicable among 349 
medical and non-medical conditions, while others focus on specific populations; some 350 
can be potentially dynamic, resulting either in the context of individual psychotherapy or 351 
group sessions [19]. While previous reviews have shown effectiveness of programs 352 
containing some mindfulness context in reducing binge eating, very few have tested 353 
MBIs for the same application [78]. Therefore, this essay will focus mainly on the 354 
potential therapeutic effect of MBIs. 355 
MBIs can be aggregated into two main programs, the Mindfulness-Based 356 
Cognitive Therapy (MBCT) and the Mindfulness-Based Stress Reduction (MBSR), that 357 
can be applied as they were originally concepted or be modified to address multiple 358 
conditions, including binge eating behaviours [19].  359 
Mindfulness state and awareness of individuals can be measured through 360 
scales, i.e. the Mindful Attention Awareness Scale [87], the Toronto Mindfulness Scale 361 
[88], the Five Facet Mindfulness Questionnaire [78], among others. The Mindful Eating 362 
Questionnaire, as the name suggests, is used to measure mindful eating [89]. 363 
 364 
 365 
 366 
 367 
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MBSR was created by Kabat-Zinn and colleagues and is the first contemporary 368 
model in psychology to incorporate the concept of mindfulness, originally developed 369 
and used in the context of chronic medical conditions [79]. It defends the sustained 370 
practice of mindfulness meditation, incorporating elements of Hatha Yoga, the most 371 
popular yoga system in the world, i.e. dynamic posture sets and breathing exercises. 372 
Increased, sustained awareness must apply to all internal signals, physiological, 373 
physical, cognitive and emotional, especially those who trigger binge [79]. Adapted 374 
formats include the Mindfulness-based Eating Awareness Training (MB-EAT), 375 
considered the first attempt to apply mindfulness training specifically for BED patients. 376 
This program incorporates elements of mindfulness meditation, mindful eating, self-377 
acceptance, compassion and forgiveness [80]. Although there is no established 378 
definition for mindful eating, it consists of paying close attention to the physical 379 
experience of eating, observing the physical and emotional sensations that it causes, 380 
particularly noting sensations of hunger and satiety; eating all types of food, while 381 
making conscious choices; eating slower and gaining insight into what triggers their 382 
compulsion [72]. From then, MBSR has been adapted to non-binge, obese patients 383 
[81].  384 
The MBCT integrates knowledge from CBT and MBSR therapies. The CBT 385 
component of these programs focuses on dietary restraint and planned, regular eating 386 
patterns, relying on self-monitoring and exploration of binge-eating triggers [19]. 387 
According to patient population, there were created the following therapies: the 388 
Modified MBCT for binge eating, the Mindfulness-Action based Cognitive Behavioural 389 
Therapy (MACBT), aimed at both BED and Substance Use Disorder (SUD) patients, 390 
the MBCT protocol adapted for the post-bariatric surgery population and the Mindful 391 
Moderate Eating Group (MMEG) [19]. The MMEG was created in 1994 and rewritten in 392 
2005 to incorporate mindfulness training [82, 83]. There were found substantial and 393 
sustained reductions in binge eating frequency and severity, emotional overeating, 394 
restrictive eating and poor body image with the implementation of this program [84].  395 
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 Mindfulness focuses on gaining, or increasing, emotion control, improving one’s 396 
self-perception and self-compassion and decreasing dysphoric symptoms, such as 397 
anxiety and depression, either towards the self or their interpersonal relationships, 398 
which, as mentioned before, are in the background of the development of eating 399 
disorders, e.g. BED [19, 66]. Thus, the relevance of mindfulness in the treatment of 400 
these individuals. 401 
Despite the established program, when testing for the potential benefit of these 402 
therapies in the context of disordered-eating behaviors, particularly binge eating, in the 403 
presence or absence of diagnostic criteria, researchers found not only a significant 404 
reduction in bingeing frequency [78, 85] but also in emotional and external eating [86]. 405 
Also surprising was discovering that a lesser degree of conscious control over their 406 
eating behaviors, made patients feel they had more control over their eating [85].  407 
However, the amount of time one expended in meditation didn’t relate to the reported 408 
final sense of mindfulness [85]. 409 
When it comes to weight loss, unless this is the main goal of treatment and 410 
supplemental weight-related strategies are implemented, mindfulness training, on its 411 
own, doesn’t show consistent, positive results [77, 90]. 412 
The very few studies that have compared these therapies with CBT show a 413 
similar or, to some extent, greater response with the first mentioned group [77, 91]. 414 
When combining them both, mindfulness skills were considered the most helpful part of 415 
the treatment by patients, reducing drop-out rates seen with CBT alone [84]. Unrelated 416 
to the eating components of the treatment, but specifically due to the mindfulness 417 
practice alone, patients recognized feeling happier and healthier with themselves and 418 
in their relationship with others [84].  419 
Improvement on primary and secondary outcomes remained sustained a few 420 
months after treatment [77, 84]; however, nothing can be inferred yet about long-term 421 
remission, since follow-up times are still short [77].  422 
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We are standing before a new and exciting area of scientific research, 423 
particularly for those passionate about behavior therapy, where there is still much room 424 
for improvement. Therefore, investigation is increasing. Portuguese researchers 425 
developed a new, innovating approach for BED, called the Befree program, which 426 
integrates mindfulness, psychoeducation and self-compassion skills [92]. The results 427 
are promising, as BED was eliminated up to 6-month post-intervention [92].  428 
 429 
 430 
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 434 
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Discussion  450 
Obesity is one of the most worrying, growing diseases in the world and is known 451 
to be caused by an imbalance in energy intake and energy expense. BED, the most 452 
frequent eating disorder, has become an important cause of obesity, as it increases 453 
energy intake. 454 
Despite being successful in reducing symptomatology and exploring 455 
development causes for the disease, CBT is still ineffective in about 50% of patients, 456 
and its discontinuation rates are to take into account, as 25% of patients don’t find any 457 
benefit in this therapy.  458 
Mindfulness and acceptance-based programs are a new, promising solution for 459 
these individuals. However, some challenges must be overcome.  460 
In accordance to their relatively recent appearance in the literature, most of the 461 
evidence support existing today is based on limited, experimental or observational 462 
studies [19]. Therefore, current evidence is still based on small sample sizes, non-463 
comparative, short-term analyses, variable intervention components and primary 464 
outcomes [19, 77]. Also relevant is the fact that a lot of the studies on the subject were 465 
developed before the fifth edition of DSM, including patients that may not fulfil BED 466 
criteria and, thus, not represent this population adequately [19]. Additionally, most BED 467 
patients seeking treatment are obese and so is the main study population; thus, non-468 
obese, BED patients cannot infer anything about treatment outcomes. 469 
With future, greater research, that is, with a randomized, controlled design, with 470 
larger samples and longer follow-up times, MBIs may prove important and needful in 471 
the treatment of patients with BED, as existing research already shows its 472 
effectiveness and acceptability.  473 
 474 
 475 
 476 
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